Abstract��OBJECTIVE To investigate drug-induced liver injury(DILI) in clinical pathway on patients with breast cancer and colorectal cancer and to explore whether the prophylactic use of hepatoprotective drugs can be included in the clinical pathway. METHODS Two hundred and five cases from January 2015 to March 2017 were selected. The patients were divided into two groups according to the prophylactic use of hepatoprotective drug. The incidence, time, severity and outcome of DILI, prophylactic use of hepatoprotective drugs were investigated. DILI related risk factors were screened and analyzed by logistic linear regression to discuss the necessity and opportunity of prophylactic use of hepatoprotective drugs. RESULTS Forty-three(20.98%) patients without DILI had prophylactic use of hepatoprotective drugs in 205 cases. The incidence of DILI in the non-prophylactic group was 4.88%. Both two groups hadn't occurred DILI during the first and second cycles of chemotherapy. However, there was a statistically significant difference in the rate of DILI between the prophylactic and non-prophylactic use of hepatoprotective drugs groups in the third cycles of chemotherapy(P<0.05). Multifactor analysis showed that prophylactic use of hepatoprotective drugs was a protective factor for the DILI. CONCLUSION The liver function should be reinforced during the first and second cycles of chemotherapy. The hepatoprotective drugs could be used prophylactically before the next period of chemotherapy if patient with abnormal liver function.
������,����,���,������,����,����. ���ٰ�����ֱ�����ٴ�·��������ҩ���Ը������������[J]. �й�ҩѧ��־, 2018, 53(14): 1230-1233.
ZHU Ya-ning, LI Li, ZHOU Nan, WANG Hong-ya, ZUO Yan, ZHANG Peng. Analysis of Drug-Induced Liver Injury in Clinical Pathway on Patients with Breast Cancer and Colorectal Cancer. Chinese Pharmaceutical Journal, 2018, 53(14): 1230-1233.
RAO Y F, ZHENG F Y, ZHANG X G. The immunological mechanism of drug induced liver injury[J]. Chin Pharm J(�й�ҩѧ��־),2008,43(16):1207-1210.
[2]
CSCO, CSH, UCLI. Expert panel consensus statement on prevention and standardized treatment of drug-induced liver injury in patients with blood diseases[J]. Chin J Hematol(�л�ѪҺѧ��־),2016,37(6):441-451.
[3]
YU Y C, MAO Y M, CHEN C W, et al. CSH Guidelines for the diagnosis and treatment of drug-induced liver injury[J]. Hepatol Int,2017,11(3):221-241.
[4]
ROTH A D, LEE M Y. Idiosyncratic drug-induced liver injury(IDILI):potential mechanisms and predictive assays[J]. Biomed Res Int,2017,2017(1):1-23.
[5]
YUWEN L X,LIANG P,YUAN Y H, et al. One case of patient with drug-induced liver injury induced by tumor chemotherapy[J]. Chin J New Drug Clin Reme(�й���ҩ���ٴ���־),2016,35(9):680-682.
[6]
ROBERT J F. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives[J]. Gastroenterology,2014,146(4):914-928.
[7]
SUN S J,ZHANG W. Key Points for the Treatment of Common Diseases. Phymatology(��������ҩ������Ҫ��ϵ�д��������ֲ�)[M]. Beijing:People's Medical Publishing House,2015:235-236.
[8]
YU L C,MAO Y M,CHEN C W. Guidelines for the management of drug-induced liver injury[J]. J Chin Hepatol(�ٴ��ε�����־),2015,31(11):1752-1769.
[9]
WU Y Q,WANG S R,YU B, et al. Investigation and analysis on application of hepatoprotective drugs in 124 in-patients with drug-induced liver injury [J]. Eval Anal Drug-Use Hosp Chin(�й�ҽԺ��ҩ���������),2017,17(1):99-101,104.
[10]
FONTANA R J,HAYASHI P H,GU J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset[J]. Gastroenterology,2014,147(1):96-108.
[11]
XIA Z, CHEN Q. Occurrence and prevention of chemotherapy induced liver injury in patients with hematologic malignancy[J]. J Int Med Concept Prac(�ڿ�������ʵ��), 2015, 10(5):364-366.
2018, Vol. 53 
